EU Paediatric Regulation Report ‘Positive,’ But More Investigation Needed, Legal Expert Claims
Executive Summary
The new EU report on how the Paediatric Regulation is working after 10 years is a “positive step forward,” says a legal expert, who also wants the commission to use its postponement of any future legislative changes as an opportunity to further examine – and discuss with all stakeholders – how to improve the procedure concerning pediatric investigation plans. The expert also raises concerns about some of the figures cited in the report.
You may also be interested in...
EU Approval In Sight For New ATMP, Products For XLH And Diabetes, And 2nd Biosimilar Herceptin
A new ATMP, two generics and a biosimilar got the thumbs up this week from the European Medicines Agency’s drug evaluation committee, the CHMP. The committee also recommended one product for conditional authorization and another for a pediatric use authorization, But it turned down a potential multiple myeloma therapy derived from sea squirts.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.